Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers
Capucine Baldini(Centre National de la Recherche Scientifique), Aurélien Marabelle(Institut Gustave Roussy)
Cited by 28
Related Papers
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
|Clinical Cancer Research|2016|1.2k
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
|Nature Reviews Clinical Oncology|2016|1.1k
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
|Annals of Oncology|2015|897
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
|Nature Reviews Clinical Oncology|2021|469
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
|Cell Research|2019|246